EQT to acquire Adalvo, a leading B2B dossier developer
· EQT X to acquire Adalvo, a rapidly growing, asset-light B2B dossier developer providing market-approval-ready generic drug dossiers to pharmaceutical companies · EQT will support Adalvo's next phase of growth, further investing in R&D and innovation, and advancing the operational scale-up of the business · Adalvo is uniquely positioned as a one-stop partner, combining strong business development capabilities with a flexible, customer-centric model to meet the bespoke needs of pharmaceutical companies worldwide · Adalvo plays an important role in increasing access to affordable